Detalhe da pesquisa
1.
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Cancer
; 129(1): 118-129, 2023 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36308296
2.
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Cancer
; 129(14): 2256-2265, 2023 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37151113
3.
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Value Health
; 25(2): 203-214, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35094793
4.
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Value Health
; 24(3): 377-387, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33641772
5.
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Future Oncol
; 17(5): 611-627, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33052055
6.
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US.
Expert Rev Pharmacoecon Outcomes Res
; 23(8): 911-920, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37313647
7.
Qualitative Patient Interviews to Characterize the Human Burden of Advanced Basal Cell Carcinoma Following Hedgehog Pathway Inhibitor Treatment.
Dermatol Ther (Heidelb)
; 13(8): 1747-1761, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37330458
8.
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Ther Adv Med Oncol
; 14: 17588359221105024, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35747163
9.
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Front Oncol
; 12: 1081729, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-37082098
10.
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
J Manag Care Spec Pharm
; 27(11): 1513-1525, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34351214
11.
A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice.
Drugs Real World Outcomes
; 6(4): 205-213, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-31741198
12.
Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
Pharmacoeconomics
; 34(9): 953-66, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27438706